JP2015509504A - 芳香族陽イオン性ペプチドおよびその使用 - Google Patents

芳香族陽イオン性ペプチドおよびその使用 Download PDF

Info

Publication number
JP2015509504A
JP2015509504A JP2014558892A JP2014558892A JP2015509504A JP 2015509504 A JP2015509504 A JP 2015509504A JP 2014558892 A JP2014558892 A JP 2014558892A JP 2014558892 A JP2014558892 A JP 2014558892A JP 2015509504 A JP2015509504 A JP 2015509504A
Authority
JP
Japan
Prior art keywords
arg
phe
lys
cytochrome
cardiolipin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014558892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509504A5 (enExample
Inventor
ヘーゼル エイチ ツェト
ヘーゼル エイチ ツェト
Original Assignee
コーネル ユニヴァーシティー
コーネル ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーネル ユニヴァーシティー, コーネル ユニヴァーシティー filed Critical コーネル ユニヴァーシティー
Publication of JP2015509504A publication Critical patent/JP2015509504A/ja
Publication of JP2015509504A5 publication Critical patent/JP2015509504A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
JP2014558892A 2012-02-23 2013-02-22 芳香族陽イオン性ペプチドおよびその使用 Pending JP2015509504A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602418P 2012-02-23 2012-02-23
US61/602,418 2012-02-23
PCT/US2013/027430 WO2013126775A1 (en) 2012-02-23 2013-02-22 Aromatic-cationic peptides and uses of same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017235950A Division JP2018076337A (ja) 2012-02-23 2017-12-08 芳香族陽イオン性ペプチドおよびその使用

Publications (2)

Publication Number Publication Date
JP2015509504A true JP2015509504A (ja) 2015-03-30
JP2015509504A5 JP2015509504A5 (enExample) 2016-04-14

Family

ID=49006261

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014558892A Pending JP2015509504A (ja) 2012-02-23 2013-02-22 芳香族陽イオン性ペプチドおよびその使用
JP2017235950A Pending JP2018076337A (ja) 2012-02-23 2017-12-08 芳香族陽イオン性ペプチドおよびその使用
JP2019210301A Pending JP2020059720A (ja) 2012-02-23 2019-11-21 芳香族陽イオン性ペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017235950A Pending JP2018076337A (ja) 2012-02-23 2017-12-08 芳香族陽イオン性ペプチドおよびその使用
JP2019210301A Pending JP2020059720A (ja) 2012-02-23 2019-11-21 芳香族陽イオン性ペプチドおよびその使用

Country Status (7)

Country Link
US (2) US10808008B2 (enExample)
EP (2) EP3513800B1 (enExample)
JP (3) JP2015509504A (enExample)
CN (1) CN104203262A (enExample)
AU (3) AU2013222237B2 (enExample)
CA (1) CA2865409C (enExample)
WO (1) WO2013126775A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150119552A1 (en) * 2012-04-12 2015-04-30 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US10793597B2 (en) * 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
EP3626252A1 (en) * 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2932408A1 (en) * 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
DE102015207415A1 (de) 2015-04-23 2016-10-27 Adidas Ag Verfahren und Gerät zum Verknüpfen von Bildern in einem Video einer Aktivität einer Person mit einem Ereignis
CA3010321A1 (en) * 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
CN107320711A (zh) * 2017-03-24 2017-11-07 南京大学 化合物ss‑31在制备治疗弗里德赖希共济失调及相关疾病药物中的应用
CN113544138B (zh) * 2018-12-18 2024-10-29 隐形生物治疗公司 线粒体靶向肽
WO2020131283A1 (en) 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases
CN115400201A (zh) * 2021-05-26 2022-11-29 四川大学华西医院 Ss-31在制备预防和/或治疗香烟诱导的气道炎症及慢性阻塞性肺疾病的药物中的用途
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
WO2025121297A1 (ja) * 2023-12-08 2025-06-12 サントリーホールディングス株式会社 エネルギー代謝促進用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007518818A (ja) * 2004-01-23 2007-07-12 コーネル リサーチ ファウンデイション インコーポレイテッド 酸化的損傷を低減する方法
JP2008513479A (ja) * 2004-09-16 2008-05-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アテローム性動脈硬化症および他の病理を改善するためのｇ型ペプチドおよび他の薬剤
JP2011513241A (ja) * 2008-02-26 2011-04-28 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP1968643A2 (en) * 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
CN107261380A (zh) 2011-10-17 2017-10-20 康奈尔大学 芳香族阳离子肽及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007518818A (ja) * 2004-01-23 2007-07-12 コーネル リサーチ ファウンデイション インコーポレイテッド 酸化的損傷を低減する方法
JP2008513479A (ja) * 2004-09-16 2008-05-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アテローム性動脈硬化症および他の病理を改善するためのｇ型ペプチドおよび他の薬剤
JP2011513241A (ja) * 2008-02-26 2011-04-28 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANN. N. Y. ACAD. SCI., 2005, VOL.1051, P.487-497, JPN6016045454, ISSN: 0003450340 *
ARTHERITIS & RHEUMATISM, 2005, VOL.52, NO.1, P.192-200, JPN6016045452, ISSN: 0003450339 *
J. AM. SOC. NEPHROL., 2007, VOL.18, P.213-222, JPN6016045449, ISSN: 0003450337 *
THE AAPS JOURNAL, 2006, VOL.8, NO.2, ARTICLE 32, P.E277-E283, JPN6016045451, ISSN: 0003450338 *

Also Published As

Publication number Publication date
AU2018200000A1 (en) 2018-01-25
EP2817021A1 (en) 2014-12-31
AU2019232783A1 (en) 2019-10-10
WO2013126775A1 (en) 2013-08-29
US10808008B2 (en) 2020-10-20
HK1204772A1 (en) 2015-12-04
JP2018076337A (ja) 2018-05-17
JP2020059720A (ja) 2020-04-16
CA2865409C (en) 2020-07-21
CA2865409A1 (en) 2013-08-29
CN104203262A (zh) 2014-12-10
EP3513800A1 (en) 2019-07-24
US20150010588A1 (en) 2015-01-08
US20210261613A1 (en) 2021-08-26
AU2013222237A1 (en) 2014-09-11
AU2013222237B2 (en) 2017-10-05
AU2019232783B2 (en) 2021-07-22
EP2817021A4 (en) 2015-09-09
EP3513800B1 (en) 2022-12-07
EP2817021B1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
AU2019232783B2 (en) Aromatic-cationic peptides and uses of same
JP2016000750A (ja) 芳香族カチオン性ペプチドおよびその使用
JP6480921B2 (ja) コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用
JP6434523B2 (ja) カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
AU2017261638A1 (en) Aromatic-cationic peptides and uses of same
HK1204772B (en) Aromatic-cationic peptides and uses of same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190610